Lilly Korea announced on the 9th that it had launched Ebglyss (lebrikizumab) in Korea for the treatment of moderate-to-severe atopic dermatitis. 

Ebglyss is a novel biologic agent that selectively blocks cytokine interleukin (IL)-13, a major cause of atopic dermatitis.

It was approved by the Ministry of Food and Drug Safety in August 2024 for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older (weighing at least 40 kilograms) who are inadequately controlled by topical treatments or for whom such treatments are not recommended.

Ebglyss demonstrated its clinical efficacy and safety profile in a pivotal Phase III cl